All articles by William Newton
William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, healthcare business and regulation, and new technologies. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
William Newton
@WillNewton19
Hansa, Genethon to test imlifidase as gene therapy pre-treatment
Hansa Biopharma and Genethon look to neutralise anti-AAV antibodies prior to gene therapy treatment as part of a new collaboration.
FDA lifts partial hold on Inhibrx rare bone cancer trials
Inhibrx will resume enrollment of two trials in chondrosarcoma after amending their protocols in response to a partial clinical hold.
Inhibikase announces updates to early-stage Parkinson’s disease program
Inhibikase will employ a newly-validated biomarker analysis to bolster its ongoing Phase IIa trial targeting untreated Parkinson’s disease.
FDA greenlights Virios’s Phase III fibromyalgia program
Virios received positive initial feedback from the FDA for a Phase III program in fibromyalgia following mixed Phase II data.
SciNeuro looks to give GSK Alzheimer’s program new life
SciNeuro launched a Phase I study of a new Lp-PLA2 inhibitor for neurodegenerative diseases after licensing GSK’s Lp-PLA2 inhibitor program last year.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Totus eyes eventual path to accelerated approval after Phase I cancer trial launch
Totus looks to carve a spot in the cancer space by targeting tough-to-treat cancers with a PI3Kα mutation.
Revolo has positive data but unanswered questions in Phase II allergy trial
Revolo Biotherapeutics achieves positive Phase IIa results in eosinophilic esophagitis, but crucial secondary endpoint data remains undisclosed.
Nova Mentis starts Phase II trial of psilocybin in fragile X syndrome
Nova Mentis will test microdoses of psilocybin in ten patients with fragile X syndrome, the leading cause of autism spectrum disorder.
Anixa’s breast cancer vaccine shows promise in Phase I trial
Anixa’s vaccine targets the protein α-lactalbumin, which appears on triple-negative breast cancer cells but not on normal cells.
Inovio reports new data for Ebola booster vaccine
Inovio announced promising new early data for its Ebola booster vaccine candidate, offering new hope for a DNA vaccine pipeline with mixed past success.